Sequencing of treatment in advanced unresectable colorectal cancer

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

This article reviews the various systemic therapy options for patients with metastatic colorectal cancer (CRC) that is judged to be noncurable. The choice of initial therapy depends on patient preferences, treatment goals, performance status, and presence of comorbid conditions. Whether surgical resection of the primary tumor should be considered in patients who present with metastatic CRC is a matter of controversy. The components of the initial systemic regimen influence the options for second- and third-line options when disease progression occurs during therapy. The standard of practice is often to continue chemotherapy until progression, unacceptable side effects, or death. In patients with incurable CRC, the balance between efficacy, toxicity, and repeated hospital or clinic visits must be discussed with the patient. Although continuous treatment may be appropriate for some patients, intermittent treatment strategies or maintenance with the least toxic agents may be preferable for others. If disease progression occurs during a chemotherapy break or while the patient is on maintenance therapy, previously used agents may be reintro-duced provided that preexisting toxicities have resolved.

Original languageEnglish (US)
Pages (from-to)S28-S37
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume11
Issue numberSUPPL.4
StatePublished - Sep 1 2013

Fingerprint

Colorectal Neoplasms
Therapeutics
Disease Progression
Drug Therapy
Patient Preference
Poisons
Ambulatory Care
Maintenance
Neoplasms

ASJC Scopus subject areas

  • Oncology

Cite this

Sequencing of treatment in advanced unresectable colorectal cancer. / Grem, Jean L.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 11, No. SUPPL.4, 01.09.2013, p. S28-S37.

Research output: Contribution to journalArticle

@article{c77807b9ffde413e90f90363d8beebcc,
title = "Sequencing of treatment in advanced unresectable colorectal cancer",
abstract = "This article reviews the various systemic therapy options for patients with metastatic colorectal cancer (CRC) that is judged to be noncurable. The choice of initial therapy depends on patient preferences, treatment goals, performance status, and presence of comorbid conditions. Whether surgical resection of the primary tumor should be considered in patients who present with metastatic CRC is a matter of controversy. The components of the initial systemic regimen influence the options for second- and third-line options when disease progression occurs during therapy. The standard of practice is often to continue chemotherapy until progression, unacceptable side effects, or death. In patients with incurable CRC, the balance between efficacy, toxicity, and repeated hospital or clinic visits must be discussed with the patient. Although continuous treatment may be appropriate for some patients, intermittent treatment strategies or maintenance with the least toxic agents may be preferable for others. If disease progression occurs during a chemotherapy break or while the patient is on maintenance therapy, previously used agents may be reintro-duced provided that preexisting toxicities have resolved.",
author = "Grem, {Jean L}",
year = "2013",
month = "9",
day = "1",
language = "English (US)",
volume = "11",
pages = "S28--S37",
journal = "JNCCN Journal of the National Comprehensive Cancer Network",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "SUPPL.4",

}

TY - JOUR

T1 - Sequencing of treatment in advanced unresectable colorectal cancer

AU - Grem, Jean L

PY - 2013/9/1

Y1 - 2013/9/1

N2 - This article reviews the various systemic therapy options for patients with metastatic colorectal cancer (CRC) that is judged to be noncurable. The choice of initial therapy depends on patient preferences, treatment goals, performance status, and presence of comorbid conditions. Whether surgical resection of the primary tumor should be considered in patients who present with metastatic CRC is a matter of controversy. The components of the initial systemic regimen influence the options for second- and third-line options when disease progression occurs during therapy. The standard of practice is often to continue chemotherapy until progression, unacceptable side effects, or death. In patients with incurable CRC, the balance between efficacy, toxicity, and repeated hospital or clinic visits must be discussed with the patient. Although continuous treatment may be appropriate for some patients, intermittent treatment strategies or maintenance with the least toxic agents may be preferable for others. If disease progression occurs during a chemotherapy break or while the patient is on maintenance therapy, previously used agents may be reintro-duced provided that preexisting toxicities have resolved.

AB - This article reviews the various systemic therapy options for patients with metastatic colorectal cancer (CRC) that is judged to be noncurable. The choice of initial therapy depends on patient preferences, treatment goals, performance status, and presence of comorbid conditions. Whether surgical resection of the primary tumor should be considered in patients who present with metastatic CRC is a matter of controversy. The components of the initial systemic regimen influence the options for second- and third-line options when disease progression occurs during therapy. The standard of practice is often to continue chemotherapy until progression, unacceptable side effects, or death. In patients with incurable CRC, the balance between efficacy, toxicity, and repeated hospital or clinic visits must be discussed with the patient. Although continuous treatment may be appropriate for some patients, intermittent treatment strategies or maintenance with the least toxic agents may be preferable for others. If disease progression occurs during a chemotherapy break or while the patient is on maintenance therapy, previously used agents may be reintro-duced provided that preexisting toxicities have resolved.

UR - http://www.scopus.com/inward/record.url?scp=84887224411&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887224411&partnerID=8YFLogxK

M3 - Article

C2 - 24158968

AN - SCOPUS:84887224411

VL - 11

SP - S28-S37

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

SN - 1540-1405

IS - SUPPL.4

ER -